Kornimate/medical-research-clean huggingface dataset:
aortic calcification and vitamin k antagonists

Conditions: Vascular Calcification

Summary: the vitamin k antagonists (vka) are necessary drugs of prevention and treatment of thrombo-embolic disease. the avkal study assesses the impact of vka treatment on the aortic calcifications development. this is a biomedical research without health product, transversal and monocentric study which compares the aortic calcifications levels of two populations : one treated by vka and the other which has never been treated by vka.

the vitamin k antagonists exercise their anticoagulant effect by preventing the vitamin k dependant gamma-carboxylation of coagulation ii, vii, ix and x factors which forms the final step of their activation. they inhibit the vitamin k epoxide reductase vkorc1 enzyme, which is responsible of the vitamin k epoxide recycling in vitamin k hydroquinone (its reduced form). the carboxylation also can be inhibited by the matrix gla protein (mgp), inhibitor factor of vascular calcifications. warfarin (the most used vka at the word level) is employed on animal for produce vascular calcifications by inhibiting the mgp activation. epidemiologic data indicate that warfarin could increase the calcifications of cardiac valves and coronary arteries. however, these studies were not interested in abdominal aorta's calcifications which are considered like an important marker of cardiovascular risk and did not concern the fluindione which is the most used vka in france. even if a class effect seems logical, the investigators can't dismiss the local effects, different to warfarin. in these studies, the calcifications assessment were rarely quantitative and the mgp levels were not measured. the vascular calcifications constitute a potential adverse effect of vka which could limit their benefit in certain populations. in this work there is an assumption that the aortic calcifications levels are upper in patients receiving vka than in patients who are not receiving vka and the aortic calcifications increase is owed to the non-activation of mgp. the main objective is to assess if the taking of vka is associated with the aortic calcifications development in patients receiving vka. investigators will compare 2 populations: one group treated by vka treatment for at least 6 months and one focus group which have never been treated by vka treatment.

Eligibility criteria:
inclusion criteria: * patients having a abdominal scanner without injection planned at chu amiens * group treated by vka: vka treatment for at least 6 months * group not treated by vka: no antecedent of avk treatment exclusion criteria: * abdominal scanner contre indication * progressive cancer * scanner planned by emergency department * patient having had acute cardiovascular accident in the last 3 months

Keywords: vascular calcification aortic calcification vitamin k antagonist fluindione warfarin matrix gla protein
pharmacokinetics of dalteparin in patients with impaired renal function

Conditions: Renal Insufficiency

Summary: low molecular weight heparins (lmwh) have been shown to be at least as efficient and safe as unfractioned heparin (ufh) in prophylaxis and treatment of venous thromboembolic events and in therapy of acute cardiovascular diseases. lmwh are widely used as safe replacement of oral anticoagulation with vitamin k antagonists (vka). due to their pharmacokinetic characteristics, lmwh tend to accumulate in patients with impaired renal function. official guidelines recommend therefore to use lmwh controlled by anti-xa levels or to use ufh instead of lmwh to provide full therapeutic anticoagulation therapy in patients with severe renal insufficiency. although dosage recommendations have been proposed for enoxaparin in patients with renal impairment based on several studies, these data cannot be applied to other lmwh directly due to different pharmacokinetic properties of each drug. the present study aims to clarify the pharmacokinetics of dalteparin in patients with renal insufficiency, especially addressing the question of accumulation after multiple doses and including patients with severe renal insufficiency and derive a safe and suitable concept for using dalteparin in patients with impaired renal function.


Eligibility criteria:
inclusion criteria: * patient starting with dalteparin for prophylaxis or therapy by order of the treating physician (after having evaluated clinical indication and contraindications). * renal function normal or impaired with or without dialysis therapy according to open study groups * age \>= 18 years * written informed consent exclusion criteria: * pregnancy / lactation * dalteparin or other lmwh already in use for \> 1 day, unless just in use during hemodialysis * anti-xa level before first application of dalteparin \> 0.3 u / ml * participation in another study * anuria or glomerular filtration rate \< 10 ml/min without dialysis * patient on intensive care unit (icu) * cardiovascular unstable patient or probable need for a quick stop of anticoagulation (e.g. emergency surgery) * patient with a disease whose estimated life expectancy is \< 28 days
postoperative infectious complications calculator for elderly patients

Conditions: Postoperative Infection; Geriatrics; Prediction

Summary: the investigators established a first-ever convenient scoring system for clinicians to assess the risk of postoperative infectious complications (pics) for elderly patients. our scoring system can aid in the early detection of potential risks for postoperative infections. higher-score patients were more likely to experience postoperative infections.

background: postoperative infectious complications (pics) are related to increased morbidity, mortality, and costs, especially in elderly patients. however, published prediction models of pics are rarely based on elderly patients. objective: the study wanted to identify practical and valuable variables that could be used to predict postoperative infections and establish a convenient scoring system for clinicians to assess the risk of such conditions in elderly patients. methods： data from 2 population-based cohorts of elderly patients undergoing non-cardiac and non-neurology surgery were used to derive and validate multivariable logistic regression models. the risk prediction models were derived from 37230 patients hospitalized in the first medical center of the chinese pla general hospital (january 2012 - august 2018). the risk prediction models were externally validated with data from a cohort of 10252 patients hospitalized in henan provincial people's hospital (november 2014 to may 2022).

Eligibility criteria:
inclusion criteria: 1. age ≥ 65 years and 2. patients undergoing surgery with anesthesia. exclusion criteria: 1. patients undergoing neurosurgery or cardiac surgery, 2. preoperative infectious diseases, and 3. patients with ≥50% of data missing.

Keywords: postoperative infectious complications elderly patients retrospective study prediction model calculator
three year follow up of a randomised controlled trial (rct) of an intervention for tobacco dependence among those with a psychotic illness

Conditions: Psychotic Disorder; Behavior, Addictive

Summary: this is a three year follow up of a previous study where researchers at unsw and unewc asked smokers with serious mental health problems to participate in a 12-month study, to assess whether intervention could assist people experiencing mental illness reduce their tobacco smoking.

between 2001 and 2003, the school of public health and community medicine at the university of new south wales carried out a large study with the centre for mental health studies at the university of newcastle. the project asked people with serious mental health problems, who also smoked cigarettes, to participate in a 12-month study, which involved completing several questionnaires/other assessments over that time with a member of the research team. around half of the participants in this study also received treatment for their smoking from the research team. this treatment involved weekly therapy with one member of the research team, and covered the relationship between smoking and mental illness, teaching people to cope with desires to smoke, how to recognise and avoid high risk situations for smoking, and how to plan alternative ways of coping with those situations where smoking usually occurred. in addition, nicotine patches were also available to assist people who made the decision to reduce their smoking. this study hoped to learn whether this new treatment could assist people experiencing mental illness reduce their tobacco smoking. after three years, previous participants were invited to participate in another follow-up assessment to check-in with their current situation, their mental health and levels of smoking.

Eligibility criteria:
inclusion criteria: * previous participants from the original study
wrinkle injection with autologous platelet rich plasma study

Conditions: Wrinkles

Summary: wrinkles result from imperfect repair of the dermal layer resulting in loss of collagen commonly due to ageing, smoking and sun exposure. platelet rich plasma (prp) contains a host of growth factors, which have been used in other clinical trials for various medical conditions such as tendonitis, and also in surgery such as the surgical repair of facial defects. results from these clinical trials suggest that prp helps in collagen formation and organisation to promote healing of tissues. this study attempts to document the clinical effects of intradermal injection of prp on wrinkles.

10 selected participants will have 10 ml of blood removed for platelet extraction with mycells®. the resulting platelet rich plasma will be injected intradermally into the facial wrinkles.

Eligibility criteria:
inclusion criteria: * adults more than 21 years of age * dis-satisfied or anxious about facial wrinkles (total wrinkle length more than 1cm) exclusion criteria: * pregnant women. * psychiatric patients. * known bleeding disorders such as platelet dysfunction syndrome, thrombocytopenia, hypofibrinogenemia * anticoagulants(eg.aspirin, warfarin) * had other wrinkle therapy for less than a month.(laser, peels, injections) * had facelift surgery for less than a year. * diseased states such as organ failure, severe anaemia, cancer, acute/chronic infections. * involved in personal litigation against an aesthetic service provider

Keywords: platelet rich plasma prp wrinkles mycells® create life source medical centre dr tan kok leong
evaluation of the xen implant in moderate primary open angle glaucoma (poag) participants

Conditions: Primary Open Angle Glaucoma

Summary: the objective of this study was to evaluate the aquesys xen implant \[xen® gel stent (xen45 implant)\] for the treatment of moderate primary open angle glaucoma (poag) participants when medications have failed to control intraocular pressure (iop). effectiveness was evaluated by comparing medicated preoperative iop to postoperative values. additionally, the number of topical iop-lowering medications at screening were compared to the number of iop-lowering medications at 1 year.


Eligibility criteria:
inclusion criteria: * diagnosis of primary open angle glaucoma * participants are taking at least one and no more than four topical iop-lowering medications. exclusion criteria: * angle closure glaucoma * participant has neovascular, uveitic or angle recession glaucoma or any glaucoma associated with vascular disorders * clinically significant inflammation or infection in the study eye within 30 days prior to the preoperative visit (e.g., blepharitis, conjunctivitis, keratitis, uveitis, herpes simplex infection) * presence of conjunctival scarring or prior conjunctival surgery or other conjunctival pathologies (e.g., pterygium) in the target quadrant

Keywords: xen primary open angle glaucoma filtration device ab interno
efficacy and safety of dexamethasone prevention for patients of ovarian hyperstimulation syndrome

Conditions: Ovarian Hyperstimulation Syndrome

Summary: this prospective, randomized, controlled clinical trial will evaluate the effect and security of dexamethasone prevention for patients of ovarian hyperstimulation syndrome.

ovarian hyperstimulation syndrome (ohss) is a iatrogenic complication of ovarian stimulation,which in its severe form is associated with significant morbidity and can be life threatening. it is characterized by cystic enlargement of the ovaries and rapid fluid shifts from the intravascular compartment to the third space. it is thought that increased vascular permeability is the pivotal mechanism of ohss pathophysiology. the administration of human chorionic gonadotrophin results in the release of vasoactive substance such as vascular endothelial growth factor that causes vasodilation and leakage of fluids. glucocorticoids and their synthetic derivatives have an inhibitory effect on the vegf gene expression in vascular smooth muscle cells. by reducing leukocytic infiltration and the release of inflammatory mediator, inhibiting vasodilation and preventing increases in vascular permeability, these agents can dampen the inflammatory response and prevent edema formation ,thus offering a potential therapeutic intervention for ohss. investigators have observed more than a hundred patients in clinical practice that low-dose dexamethasone has prevention action for patients in ivf cycles at high risk of ohss. this clinical trial is designed to evaluate the effect and security of dexamethasone prevention for patients of ovarian hyperstimulation syndrome. there are two groups: bromocriptine group, dexamethasone group .after followed-up for 7 days , clinical ohss parameters will be collected at oocyte retrieval and at the 4rd d and 6th d of treatment .

Eligibility criteria:
* inclusion criteria: * women of reproductive age * women having controlled ovarian hyperstimulation as part of any assisted reproductive technique * women at risk of severe ohss(serum estradiol levels were\>3000pg/ml on the day of hcg trigger ; there was retrieval of 20 or more oocytes) * exclusion criteria: * unwillingness to comply with the study protocol. * attending other clinical trials in the same period. * chronic glucocorticoid their synthetic derivatives intake. * history of allergic to study medications. * the patients who cannot take dexamethasone.： hypertension, diabetes,gastric ulcer; abnormal renal or hepatic function and so on.

Keywords: ovarian hyperstimulation syndrome dexamethasone
factors associated with quality of life in chronic low back pain

Conditions: Chronic Low-back Pain (cLBP)

Summary: the aim of this study was to identify and validate the factors that may affect quality of life in patients with chronic low back pain.

participants between the ages of 18-65, who are willing to participate in the study and have low back pain for more than 3 months will be included in the study. the necessary demographic information will be obtained with a data form. for the evaluation; visual analogue scale (vas), tampa kinesiophobia scale, fear-avoidance beliefs questionnaire, roland-morris disability questionnaire, beck depression scale, self-efficacy for managing chronic disease 6-item scale, coping strategies inventory short form (csi-sf), pain catastrophising scale, pittsburgh sleep quality index, short form - 36 (quality of life questionnaire) will be used. the data obtained in the study will be entered into spss 17 package programme (greasley, 2007). minimum-maximum values, arithmetic mean and standard deviation will be used to evaluate numerical data, and frequency distributions and percentages will be used to summarise categorical data. the data of the study will be analysed using analysis of moment structures (amos) statistical package programmes. in all analyses, p\<0.05 will be considered statistically significant.

Eligibility criteria:
inclusion criteria: * volunteering to participate in the study * having low back pain for more than 3 months * being between the ages of 18-65 exclusion criteria: * history of surgery in the spinal region * rheumatoid arthritis * tumour * autoimmune disease * neurological disease * psychiatric or cognitive impairment
detection of electrodermal activity in pain 2

Conditions: Cancer; Chronic Obstructive Pulmonary Disease (COPD; Pain

Summary: the goal of this study is to investigate the association between self-reported pain and electrodermal activity and to create an algorithm that detects pain and provides timely alarms for rising pain levels in patients with life-threatening illnesses suffering from persistent pain. the study is exploratory. hypothesis: electrodermal activity can distinguish different pain intensity levels in patients with chronic pain and a life-threatening disease. methodology: thirty-seven patients with cancer and/or chronic obstructive pulmonary disease (copd) will be identified through hospital record screening. these patients will wear a monitoring device for a maximum of one week and report their pain intensity throughout the day. analysis: discriminant analysis will be used to differentiate between mild, moderate, and severe pain. this study is exploratory, generating hypotheses for subsequent phases of the project.

methods the study is a phase 2 trial, preceded by a phase 1 trial that included healthy volunteers. patients will be inpatients and outpatients at department of pulmonary and endocrine diseases, hvidovre hospital. measures subjective measures (self reported) pain. pain intensity (interval, 0 to 10) is measured using the nrs, a commonly used tool asking patients to rate their pain intensity on a scale from 0 to 10, with 0 indicating no pain and 10 reflecting the worst possible pain. patient health status. the patient health questionnaire (phq-9) is used to provisionally diagnose depression and grade severity of symptoms in general medical and mental health settings. the phq-9 is the depression module. ambulatory assessment. the patient group in phase 2 will be asked to wear a wristband device for 1 week. during this period, a prompt will be sent on a smartphone connected to a wearable device provided by movisens gmbh, five times a day (9 am, 12 pm, 3 pm, 6 pm, and 9 pm) to answer questions about their current pain levels using the nrs scale. objective measures electrodermal activity. a wearable device provided by movisens gmbh will be used to record skin conductance measured in microsiemens (μs). wearable device the edamove 4 device provided by movisens gmbh consists of an eda and activity sensor. it records eda signals to monitor both tonic and phasic electrical activity in the skin.

Eligibility criteria:
inclusion criteria: * danish * age over 18 * persistent or recurrent pain (longer than three months) * cancer: dc01-dc9 or pulmonary diseases:dj40-dj47 exclusion criteria: * a current diagnosis with psychological/ psychiatric disorders * impaired cognitive function * substance abuse * a skin condition on the to-be-tested body parts * phq-9 reveals suicidal ideation

Keywords: pain electrodermal activity pain detection pain prediction galvanic skin response wearable pain monitoring
measurement of midazolam levels in follicular fluid

Conditions: Midazolam Overdose

Summary: to determine the impact of midazolam levels in follicular fluid on morpho-kinetics and morpho-genetics. the reason to measure midazolam levels in larger size follicles in this study is to maximize the chances to get a mature oocyte and therefore develop into a potential embryo to be analyzed.

the correlation of midazolam levels in follicular fluid and euploid status of the embryos is worth exploring as no data exists that suggests any influence on the quality of the embryos from using this substance for ivf since its earliest days. measuring time lapsed from injection to first oocyte retrieval as well as time lapsed in between first and last oocyte retrieved will grand insight into the rise of levels of midazolam inside the follicular fluid, correlated with the chromosomal status and the morphokinetic development of the euploid embryos.

Eligibility criteria:
inclusion criteria: * infertility (prim. / sec.) * age \>18 - ≤ 38 years. * bmi 19-30 * stimulation in gnrh-antagonist protocol, using rfsh * expected normal ovarian response (6) * at least 4 follicles with the size ≥ than 17 mm on the day of opu * patients undergoing pgs * able to understand the aim of the study and to provide consent exclusion criteria: * history of endometriosis, classified according to the american fertility society (afs) as stage 3 or more. * severe male factor

Keywords: copd,ivf
vasoactive hormones during the night in patients with obstructive sleep apnea and healthy controls.

Conditions: Healthy; Obstructive Sleep Apnea

Summary: obstructive sleep apnea syndrome is complicated by considerable cardiovascular morbidity and mortality, at least partly due to hypertension. nocturnal hypoxia, hypercapnia and acidosis stimulate chemoreceptors and presumably increased secretion of vasoactive hormones which might be responsible for hypertension in these patients. the aim of this study is to measure the secretion of vasoactive hormones at night and to analyse the relationship between vasoactive hormones, oxygen saturation and the blood pressure at night.


Eligibility criteria:
inclusion criteria: male and female age 20-65 obstructive sleep apnea exclusion criteria: drug or alcohol abuse pregnancy or breast feeding cancer clinical signs or history of disease in the heart, lungs, kidney or endocrine organs abnormal laboratory tests albuminuria or glucosuria aterial hypertension for healthy subjects

Keywords: obstructive sleep apnea vasoactive hormones blood pressure
stagewise implementation-to-target- medications for addiction treatment (sitt-mat)

Conditions: Addiction, Opioid

Summary: the purpose of this study is to expand access to medications for opioid use disorder (moud) in specialty addiction programs in washington state. sixty-four addiction treatment programs will participate in an adaptive implementation strategy trial that uses a stagewise implementation-to-target (stepped "care" type) approach whereby organizations engage in increasingly intensive implementation strategies as needed. organizations are moved to a follow-up/sustainment arm once they have met the implementation targets described below. the design also includes an external comparator arm, which consists of 510 addiction treatment programs that are not participating in the study and will mimic as study controls. the sequence of implementation strategies are: 1. enhanced monitoring and feedback 2. niatx/mat academy 3. randomization to either niatx internal facilitation or niatx external facilitation 4. assignment to niatx external facilitation if outcome targets are not achieved in the niatx internal facilitation arm implementation targets are: 1. reach - at least 75% of patients with opioid use disorder (oud) receiving moud for three consecutive months 2. adoption - at least 1 integrated moud prescriber actively prescribing moud 3. implementation - a total score ≥ 4 on the integrating medications for addiction treatment (imat) index. contextual moderators and mediators of performance on target outcomes as a function of the implementation strategy step will be examined, as will the costs associated with participation in the sequence of implementation strategies.


Eligibility criteria:
inclusion criteria: * addiction treatment programs in washington state * residential (detoxification or rehabilitation) or outpatient (intensive outpatient or outpatient) levels of care * primary care clinics, including federally qualified health centers (fqhcs) and community health centers (chcs) exclusion criteria: * opioid treatment programs

Keywords: implementation strategies medications for opioid use disorder